Ann Pediatr Endocrinol Metab.  2021 Dec;26(4):217-217. 10.6065/apem.2120143edi01.

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"

• Kim M

• KMID: 2523826
• DOI: http://doi.org/10.6065/apem.2120143edi01

Reference

References

1. Rho JG, Kum CD, Seo YJ, Shim YS, Lee HS, Hwang JS. Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs. Ann Pediatr Endocrinol Metab. 2021; 26:266–71.

2. Song SM, Youn JS, Ko JM, Cheon CK, Choi JH, Yoo HW. The natural history and prognostic factors of Graves' disease in Korean children and adolescents. Korean J Pediatr. 2010; 53:585–91.

3. Roh JG, Park KJ, Lee HS, Hwang JS. Thyrotoxic hypokalemic periodic paralysis due to Graves’ disease in 2 adolescents. Ann Pediatr Endocrinol Metab. 2019; 24:133–6.

4. Azizi F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid. 2020; 30:1451–7.

5. Glaser N, Styne D. Organization of pediatric endocrinologists of Northern California Collaborative Graves’ Disease Study Group. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics. 2008; 121:e481–8.